Cart
sales@molnova.com
Lifirafenib
CAS No. 1446090-79-4
Lifirafenib( Beigene-283 | BGB-283 )
Catalog No. M23610 CAS No. 1446090-79-4
Lifirafenib is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 95 | In Stock |
|
| 100MG | 827 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLifirafenib
-
NoteResearch use only, not for human use.
-
Brief DescriptionLifirafenib is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant respectively.
-
DescriptionLifirafenib is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant respectively.
-
In VitroLifirafenib (BGB-283) potently inhibits BRafV600E-activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRafV600E and EGFR mutation/amplification. In BRafV600E colorectal cancer cell lines, Lifirafenib (BGB-283) effectively inhibits the reactivation of EGFR and EGFR-mediated cell proliferation.
-
In VivoLifirafenib (BGB-283) treatment leads to dose-dependent tumor growth inhibition accompanied by partial and complete tumor regressions in both cell line-derived and primary human colorectal tumor xenografts bearing BRafV600E mutation.
-
SynonymsBeigene-283 | BGB-283
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorB-Raf (V600E)|EGFR|EGFR (L858R/T790M)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1446090-79-4
-
Formula Weight478.42
-
Molecular FormulaC25H17F3N4O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:100 mg/mL (209.02 mM)
-
SMILESO=C1Nc2nccc(Oc(cc3)cc(C45)c3OC4C5c3nc(ccc(C(F)(F)F)c4)c4[nH]3)c2CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Tang Z, et al. Mol Cancer Ther. 2015, 14(10):2187-97.
molnova catalog
related products
-
AZD-9291 mesylate
A potent, selective, third-generation irreversible inhibitor of mutant EGFR with IC50s of 1/12/5 nM for L858R-T790M/L858R/L861Q respectively.
-
DBPR112
DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM for EGFRWT and 48 nM for EGFRL858R/T790M, capable of occupying the ATP-binding site and demonstrating significant antitumor efficacy.
-
CHF5074
CHF5074, a γ-secretase modulator, reduces Aβ42/40 secretion (IC50: 3.6/18.4 μM).
